Alpha Cognition Inc
XTSX:ACOG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Macrotech Developers Ltd
BSE:543287
|
IN |
Alpha Cognition Inc
Total Current Assets
Alpha Cognition Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alpha Cognition Inc
XTSX:ACOG
|
Total Current Assets
$2.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Current Assets
CA$84.3m
|
CAGR 3-Years
61%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Current Assets
$492m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
40%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Current Assets
$560.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
25%
|
CAGR 10-Years
25%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Current Assets
CA$85.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
137%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Current Assets
$201.4m
|
CAGR 3-Years
107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alpha Cognition Inc
Glance View
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The Company’s therapeutic pipeline includes ALPHA-1062 and ALPHA-0602. The Company’s ALPHA-1062 development program is primarily focused on clinical and regulatory development, chemistry, manufacturing and control development, and commercial readiness. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein, and is in preclinical development for the treatment of amyotrophic lateral sclerosis. The company has three development programs: ALPHA-1062 in combination with memantine for the treatment of moderate-to-severe Alzheimer’s; ALPHA-1062 nasal formulation for the treatment of mild traumatic brain injury, and ALPHA-0602, for the treatment of amyotrophic lateral sclerosis. ALPHA-1062 is also being researched as a treatment for mild-traumatic brain injury.
See Also
What is Alpha Cognition Inc's Total Current Assets?
Total Current Assets
12.2m
USD
Based on the financial report for Dec 31, 2021, Alpha Cognition Inc's Total Current Assets amounts to 12.2m USD.
What is Alpha Cognition Inc's Total Current Assets growth rate?
Total Current Assets CAGR 1Y
58%
Over the last year, the Total Current Assets growth was 58%.
